Top Markets
Coin of the day
NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc.

NeuBase Therapeutics, Inc.

NBSE
Rank in Stocks #39174
Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics,... Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes. At the core of its approach is the proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform. This technology is being utilized to target ailments such as Huntington's disease (HD) and myotonic dystrophy, in addition to a broader spectrum of genetic conditions and applications within oncology. The company's leading therapeutic candidates encompass NT0100, a PATrOL-powered anti-gene therapy for Huntington's disease; NT0200, another PATrOL-enabled anti-gene solution for myotonic dystrophy type 1; and NT0300, a PATrOL-based treatment specifically engineered to address the mutated KRAS gene. NeuBase Therapeutics, Inc. maintains its headquarters in Pittsburgh, Pennsylvania.
Share Price
$0.378
Last synced: 2024-05-24
Market Cap
$618.41K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade NeuBase Therapeutics, Inc. (NBSE)

Category

Stock split history for NeuBase Therapeutics, Inc. (NBSE)
NeuBase Therapeutics, Inc. stock (symbol: NBSE) underwent a total of 0 stock splits.
The most recent stock split occurred on Aug 14, 2026.
One NBSE share bought prior to Aug 14, 2026 would equal to 0 NBSE shares today.
Stock split list
Year Split Multiple Cumulative Multiple
Not enough data for the provided dates.
Stock splits for similar companies or competitors
Company Number of stock splits Cumulative Multiple Country
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE